ArticleCellular and molecular life sciences : CMLS2026
M1 receptor modulator VU0364572 attenuates cortico-thalamo-striatal transmission and facilitates cocaine CPP extinction.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cocaine use disorder (CUD), marked by persistent drug-seeking and frequent relapse, remains without an effective pharmacological therapy. Modulation of the M1 muscarinic receptor has emerged as a promising therapeutic strategy. VU0364572, a reported M1 receptor bitopic partial agonist, has been shown to reduce excitatory transmission onto the nucleus accumbens (NAc), a key region implicated in addiction. However, its effects on specific excitatory inputs to the NAc remain unclear. In this study, we combined whole-cell electrophysiology with viral circuit tracing to examine how VU0364572 modulates excitatory transmission of the prefrontal cortex (PFC)➜NAc and paraventricular nucleus of the thalamus (PVT)➜NAc pathways. We found that VU0364572 attenuates excitatory input from both PFC and PVT regions. Notably, we also observed a reduction in excitatory transmission from PFC to PVT neurons that project to the NAc, suggesting suppression of excitation within the polysynaptic PFC➜PVT➜NAc pathway. In cocaine-conditioned place preference experiments, repeated VU0364572 facilitated the extinction of cocaine-seeking behavior, suggesting an inhibitory effect on CUD behavior. Reductions in excitatory synaptic transmission in the NAc were present two weeks post administration, indicating a sustained action of VU0364572. These findings suggest that M1 receptor modulation by VU0364572 suppresses excitatory drive to the NAc through both direct (PFC➜NAc) and polysynaptic (PFC➜PVT➜NAc) pathways. Further, inhibitory actions in the NAc are persistent, which could underlie long-term behavioral effects. Taken together, our findings support the potential of VU0364572 as a therapeutic targeting both motivational and affective-related circuits in CUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.